Ger­man Mer­ck bests US Mer­ck in UK copy­right tus­sle of Mer­ck v. Mer­ck

6 years ago
Pharma

The man who led Gilead’s au­toim­mune piv­ot heads to Boston; No­var­tis gets a new chief for its AI In­no­va­tion Cen­ter

6 years ago
Peer Review

FDA ap­proves the first gener­ic for Amar­in's Vas­cepa — but is a fish oil price war im­mi­nent?

6 years ago
Pharma
FDA+

GSK inks $231M man­u­fac­tur­ing deal as Hal Bar­ron an­tic­i­pates fruit­ful year for pruned R&D group

6 years ago
Outsourcing

Roche beefs up di­ag­nos­tic arm with an­oth­er bet on faster, cheap­er DNA se­quenc­ing

6 years ago
Deals

Covid-19 roundup: CanSi­no beats Mod­er­na to pub­li­ca­tion of first-in-hu­man da­ta for a coro­n­avirus vac­cine

6 years ago
Coronavirus

Parkin­son's pa­tients no longer need to re­ly on a nee­dle for apo­mor­phine an­ti­dote for 'of­f' episodes af­ter new FDA ...

6 years ago
Pharma
FDA+

A new biotech from a long­time de­vel­op­er wants to bring the tar­get­ed can­cer rev­o­lu­tion to the kids left be­hind

6 years ago
R&D

Eu­ro­pean reg­u­la­tors ac­cept Fi­bro­Gen's ane­mia drug for re­view; Pas­sage Bio's lead gene ther­a­py gets more love from the ...

6 years ago
News Briefing

Kad­mon kicks off 're­al-time' NDA sub­mis­sion with an­oth­er look at 're­mark­able' chron­ic graft-ver­sus-host-dis­ease da­ta

6 years ago
R&D

Once val­ued at $4B, an em­bat­tled Ako­rn — nurs­ing a mar­ket cap of rough­ly $37M — files for bank­rupt­cy

6 years ago
Pharma
FDA+

Be­zos, Paul Allen funds, a16z put up $100M to build an Il­lu­mi­na of hu­man pro­teins

6 years ago
Financing
Startups

As CEO bounces back from Covid-19, Apel­lis says FDA meet­ing clears path to file for an OK on Soliris ri­val

6 years ago
R&D
FDA+

HotSpot an­nounces $65M Se­ries B, as Nim­bus pi­o­neers look to keep up in a crowd­ing field

6 years ago
R&D

Gilead, Gala­pa­gos claim PhI­Ib/III win for fil­go­tinib in ul­cer­a­tive col­i­tis — which pales in com­par­i­son to ri­vals

6 years ago
R&D

EMA ex­tends vir­tu­al-on­ly meet­ing pol­i­cy through Au­gust

6 years ago
FDA+
Coronavirus

Covid-19 roundup: BAR­DA hands As­traZeneca $1B-plus to race through PhI­II and ramp up fall de­liv­er­ies of Ox­ford’s ...

6 years ago
Coronavirus

Mam­moth Bio­sciences teams with GSK to put Covid-19 CRISPR tests at home, air­ports, bor­ders

6 years ago
Coronavirus

Covid-19 roundup: Hit with new con­flict ac­cu­sa­tions, Janet Wood­cock steps out of the agen­cy's Covid-19 chain of ...

6 years ago
R&D
Coronavirus

Si­lence Ther­a­peu­tics wants to list on Nas­daq while pur­su­ing new deals; Sur­face On­col­o­gy inks lat­est Keytru­da ...

6 years ago
News Briefing

Phar­mas­set co-founder jumps in­to Covid-19 fight, with a new com­pa­ny and $215 mil­lion to get there

6 years ago
Financing
Coronavirus

An­dreessen Horowitz backs a new mol­e­cule builder from UCLA equipped with the lat­est in con­ver­gence tech. And he’s ...

6 years ago
People
Financing

George Church spin­off swal­lows a key man­u­fac­tur­ing part­ner as it preps CRISPR-edit­ed pig or­gans for an­i­mal test­ing

6 years ago
Deals

A lit­tle-known biotech run­ning low on cash looks to get its own $100M IPO from pan­dem­ic mar­ket

6 years ago
Financing
First page Previous page 840841842843844845846 Next page Last page
A service from the Financial Times